Young Kwon is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Young held various leadership roles as a senior executive at Momenta Pharmaceuticals, most recently as Chief Financial and Business Officer, where he was responsible for business development, strategy, finance, investor relations, and commercial. During his tenure at Momenta, Young led public equity financings raising nearly $500 million, and led the company’s sale to Johnson & Johnson for $6.5 billion.
Before Momenta, Young was a business development professional at Biogen, driving various transactions, and worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies.
Young is a member of the board of directors of ADMA Biologics (Nasdaq: ADMA) and is an advisor to Lightstone Ventures, a venture capital firm investing in biotech and medical device companies. He earned a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University and a BS in Biology from the Massachusetts Institute of Technology.